Vertex Pharmaceuticals Incorporated Dossier

Vertex Pharmaceuticals Incorporated reported total revenues of $2.96 billion and operating income of $1.15 billion for the second quarter of 2025. These results were generated primarily through the continued commercial execution of the company's cystic fibrosis medicines, specifically the TRIKAFTA/KAFTRIO franchise.

Financial Highlights

* Reported total product revenues of $2.96 billion for the quarter ended June 30, 2025

* Generated operating income of $1.15 billion in the second quarter of 2025

* Achieved net income of $1.03 billion and diluted earnings per share of $3.99 for the second quarter

* Recorded $2.55 billion in revenue from the TRIKAFTA/KAFTRIO segment in the second quarter

* Projected full-year 2025 total product revenues between $10.85 billion and $11.0 billion

* Maintained $6.38 billion in cash and cash equivalents as of June 30, 2025

* Held $5.65 billion in long-term marketable securities at the end of the second quarter

* Forecasted combined non-GAAP R&D, AIPR&D, and SG&A expenses... Sign in / Sign up to learn more about Vertex Pharmaceuticals Incorporated

Continue your research by chatting with our AI financial analyst about Vertex Pharmaceuticals Incorporated. Ask follow-up questions, request specific analysis, or explore investment scenarios. All insights are grounded in verified financial data and SEC filings.

Start your analysis with these investor-focused questions:

• Given Vertex Pharmaceuticals Incorporated's FY2025 revenue is still dominated by its cystic fibrosis franchise, how do the early revenue trends for new products like ALYFTREK, CASGEVY, and JOURNAVX assess the initial success of its pipeline diversification strategy?
• Vertex Pharmaceuticals Incorporated's guidance for FY2025 includes combined non-GAAP R&D and SG&A expenses of up to $5.0 billion. How does this significant investment level compare to the near-term revenue potential of its late-stage pipeline assets, such as povetacicept and inaxaplin?
• Considering the recent FDA Breakthrough Therapy Designation for povetacicept in IgA nephropathy, how should analysts adjust their valuation models for Vertex Pharmaceuticals Incorporated to account for the de-risking of its kidney disease portfolio?
• In Q2 FY2025, Vertex Pharmaceuticals Incorporated generated over $1.1 billion in operating income while also spending nearly $1 billion on R&D. How does this balance between high current profitability and aggressive R&D investment position the company against competitors in its new target markets like pain and autoimmune diseases?
• With a strong net cash position and no debt reported in FY2025, evaluate the capital allocation strategy of Vertex Pharmaceuticals Incorporated, specifically its balance between share buybacks and the potential for further strategic acquisitions to bolster its non-CF pipeline.